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COMMENTARY
Cdk5 activity in the brain – multiple paths of regulation
Kavita Shah1,* and Debomoy K. Lahiri2
ABSTRACT
Cyclin dependent kinase-5 (Cdk5), a family member of the cyclin-
dependent kinases, plays a pivotal role in the central nervous system.
During embryogenesis, Cdk5 is indispensable for brain development
and, in the adult brain, it is essential for numerous neuronal
processes, including higher cognitive functions such as learning
andmemory formation. However, Cdk5 activity becomes deregulated
in several neurological disorders, such as Alzheimer’s disease,
Parkinson’s disease and Huntington’s disease, which leads to
neurotoxicity. Therefore, precise control over Cdk5 activity is
essential for its physiological functions. This Commentary covers
the various mechanisms of Cdk5 regulation, including several
recently identified protein activators and inhibitors of Cdk5 that
control its activity in normal and diseased brains. We also discuss
the autoregulatory activity of Cdk5 and its regulation at the
transcriptional, post-transcriptional and post-translational levels. We
finally highlight physiological and pathological roles of Cdk5 in the
brain. Specific modulation of these protein regulators is expected to
provide alternative strategies for the development of effective
therapeutic interventions that are triggered by deregulation of Cdk5.
KEY WORDS: Cdk5, p25, p35, b-Amyloid, Excitotoxicity, Cdk,
Cyclins, Neurodegeneration, Alzheimer’s disease, Synaptic
plasticity, Learning and memory, Pain signalling, Neuronal
migration, Axonal growth, Synaptogenesis
Introduction
Cyclin-dependent kinases (Cdks) are Ser/Thr protein kinases that
associate with specific cyclin subunits in order to be activated.
This family currently includes 11 classic Cdks (Cdk1 – Cdk11)
and two new family members (Cdk12, Cdk13) (Malumbres et al.,
2009). All Cdks phosphorylate Ser-Pro or Thr-Pro sites, with a
preference for the basic residues Lys and Arg at proximal
upstream and downstream positions. Cdks are highly expressed in
proliferating cells and play indispensable roles in specific phases
of cell cycle.
The first human Cdk was cloned in 1987 by using functional
complementation in yeast, and was termed cell division cycle 2
(Cdc2; now officially known as Cdk1) because of its high
homology with fission yeast kinase Cdc2 (Lee and Nurse, 1987).
The second human homolog of the Cdk family to be cloned from a
human cDNA library was kinase Cdk2 (Elledge and Spottswood,
1991; Ninomiya-Tsuji et al., 1991; Tsai et al., 1991). The discovery
of human Cdk1 and Cdk2 paved the way for the identification of
Cdk5 (Gene ID: 1020); and in 1992, five independent laboratories
reported Cdk5 as a new member of the Cdk family, although each
study gave it a different name, i.e. tau kinase II (Ishiguro, et al.,
1992), neuronal Cdc2 like kinase (nclk) (Hellmich et al., 1992),
brain proline-directed kinase (Lew et al., 1992), PSSALRE
(Meyerson et al., 1992) and Cdk5 (Xiong et al., 1992).
Cdk5, although highly homologous to its relatives, is a unique
Cdk family member (Dhavan and Tsai, 2001). Cdk5 is
ubiquitously expressed, but its functions are vital in post-
mitotic neurons, where other Cdks are not expressed or active.
In contrast to other Cdks, Cdk5 does not participate in cell cycle
progression in proliferating cells, but can aberrantly activate
various components of cell cycle when it is deregulated in post-
mitotic neurons, leading to cell death (Chang et al., 2012).
For its activation Cdk5 also requires its specific binding
partners CDK5R1 and CDK5R2 (hereafter referred to as p35 and
p39, respectively) (Tsai et al., 1994; Tang et al., 1995).
Furthermore, unlike other family members, Cdk5 is not regulated
by the cyclin-dependent kinase inhibitors CDKN1A and CDKN1B
(hereafter referred to as p21Cip1 and p27Kip1, respectively) that,
thus, have crucial roles in the regulation of Cdks.
Accumulating evidence has revealed a plethora of Cdk5
functions in neuronal and non-neuronal cells. During
embryogenesis, Cdk5 is indispensable for normal brain
development (Ohshima et al., 1996), whereas – in adult brains
– it regulates neuronal survival, synaptic plasticity, learning and
memory formation, pain signaling, drug addiction and long-term
behavioral changes (Bibb et al., 2001; Fischer et al., 2002; Pareek
et al., 2006). Cdk5 is known to be deregulated in several
neurodegenerative diseases, including Alzheimer’s disease (AD),
Parkinson’s disease (PD) and Huntington’s disease (HD), which
causes neurotoxicity. Consequently, although the deregulation of
other Cdks commonly occurs in many types of cancer, Cdk5 is
emerging as a potential clinical target to treat multiple
neurodegenerative diseases (Cheung and Ip, 2012). Thus, Cdk5
is unique among the Cdks in that it employs its own activation
strategies, and has widely diverse functions in neuronal and non-
neuronal tissues with different clinical implications (Hisanaga
and Endo, 2010). In this Commentary, we discuss the
mechanisms through which Cdk5 is regulated by binding to its
protein partners in normal and diseased brains. In addition, we
describe the mechanisms by which Cdk5 and p35 are regulated at
transcriptional, post-transcriptional and post-translational levels.
Finally, we briefly highlight the various physiological and
pathological functions of Cdk5 in the brain that might be
exploited in therapeutic interventions.
Regulation of Cdk5 activity by protein partners
As noted above, Cdk5 is activated by binding it specific
activators p35 and p39 (and their cleaved products, p25 and
p29, respectively) (Fig. 1). Recent findings have further
identified cyclin I (CCNI) as an activator of Cdk5 (Brinkkoetter
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et al., 2009) (Fig. 1). Cyclin I is not known to activate other Cdk
family members, suggesting it might be a Cdk5-specific activator.
In contrast, Cdk5 is inhibited by cyclin D1 (CCND1) (Modi et al.,
2012), cyclin E (CCNE) and glutathione S-transferase P (GSTP1)
(Sun et al., 2011) (Fig. 1).
p35
p35 was the first Cdk5 activator to be identified (Fig. 1). It forms
a tertiary structure that is similar to the cyclin-box fold domain
that is required for Cdk activation, although the primary sequence
of p35 is distinct from that of cyclins (Tang et al., 1997). In fact,
the Cdk5–p35 complex has been shown to adopt a ternary
structure that is similar to the complex between Cdk2 and cyclin
A (Cdk2–cyclin-A) (Tarricone et al., 2001).
p35 is a membrane-anchored protein that comprises two parts,
an N-terminal region encompassing the p10 component and a C-
terminal region containing p25. The binding of p25 to Cdk5 leads
to its activation even in the absence of p10. Notably, p10 contains
the myristoylated region that is important for the membrane
targeting of p35. p10 also contains a signal for p35 degradation
through the ubiquitin-proteosome pathway. Consequently,
p35 has only a short half-life (t1/2520–30 minutes) and is
rapidly degraded by the proteosome.
Active Cdk5 also autoinhibits its activity by directly
phosphorylating p35. Rapid degradation of p35 is observed in
neurons that express Cdk5, which can be inhibited by expression
of a dominant-negative or kinase-dead Cdk5 mutant, or by
treatment with the Cdk5 inhibitor Roscovitine (Wei et al., 2005).
Cdk5 primarily phosphorylates p35 at amino acid residues
Ser8 and Thr138 (hereafter S8 and T138, respectively), two
phosphorylation events that are differentially regulated and have
different consequences (Kamei et al., 2007). The phosphorylation
level of S8 remains constant during development, whereas T138
phosphorylation is highest in fetal brains and undetectable in
adult brains (Fig. 2). Because both sites are phosphorylated
by Cdk5, the differential phosphorylation levels are believed to be
due to increased dephosphorylation of T138 in adult brain by
protein phosphatase 1 (PP1) or protein phosphatase 2A (PP2A)
(Kamei et al., 2007). However, further studies are needed to
confirm this possible mechanism.
Cdk5-mediated phosphorylation of p35 at S8 is required to
retain p35 in the cytoplasm (Asada et al., 2012). Consequently, a
phosphomimetic p35 S8E mutant shows cytoplasmic distribution,
whereas a phosphoresistant p35 S8A mutant accumulates in the
nucleus (Asada et al., 2012) (Fig. 2).
Importantly, phosphorylation of p35 at T138 by Cdk5 has
three functions. First, it prevents the intramolecular cleavage of
p35 to p10 and p25 by calpain, thereby preventing the formation
of p25 during brain development. As p25 formation is highly
neurotoxic (as discussed below), fetal brains might employ T138
phosphorylation to protect against neurotoxicity when Cdk5
activity is high (Fig. 2). Second, phosphorylation of p35 at T138
inhibits its microtubule (MT) polymerization activity (He et al.,
2008). A large amount of p35 in the cell binds MTs through its N-
terminal domain and promotes MT bundling (He et al., 2008)
(Fig. 2). Binding of p35 to MTs removes it from Cdk5 and
renders the kinase inactive. Cdk5-mediated phosphorylation of
p35 at T138 inhibits its binding to MTs, thereby preventing
MT bundling and neurite outgrowth (Fig. 2). Third, it increases
proteosomal degradation of p35, thereby tightly regulating its
levels. This, in turn, allows Cdk5 to autoregulate its own activity.
Collectively, these findings demonstrate that Cdk5 regulates
the stability and subcellular localization of p35 through direct
phosphorylation, which in turn allows active Cdk5 to
spatiotemporally regulate its own activity in the cells.
p25 and p10
p25, the truncated form of p35, is also a neuron-specific activator of
Cdk5 (Lew et al., 1994; Fig. 1). p25 is generated from p35 under a
variety of neurotoxic conditions, such as exposure to amyloid b
peptide (Ab), excitotoxicity, ischemia and oxidative stress (Patrick
et al., 1999; Sahlgren et al., 2006). In this context, it is important to
mention that AD is characterized by accumulation of Ab peptide as
neuritic plaques and of hyperphosphorylated tau as neurofibrillary
tangles (NFT), as well as by oxidative stress, all of which are
targeted for therapeutic interventions in AD (Lahiri et al., 2003;
Lahiri, 2011; Lahiri et al., 2014; Perez et al., 2014; Rosenmann,
2013). Notably, these neurotoxic insults disrupt the intracellular
Ca2+ homeostasis in neurons, thereby promoting activation of
calpain, which in turn cleaves p35 into p25 and p10 (Lee et al.,
2000). In agreement with this finding, calpains – particularly m- and
m-calpain – are abnormally activated in AD (Saito et al., 1993).
Similarly, calpastatin, an endogenous inhibitor of calpains, is
substantially decreased in AD (Nixon, 2003), which could lead to
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Fig. 1. Regulation of Cdk5 differs from that of other Cdk family members. (Left) Regulators of Cdk family members other than Cdk5. In proliferating cells,
these cyclin-dependent kinases are activated by classic cyclins (but not cyclin I) and inhibited by Cdk-dependent inhibitors (CKIs), e.g. p21Cip1 and p27Kip1.
Myt1 and Wee1 kinases inhibit Cdks by phosphorylation of amino acid residues T14 and Y15, respectively. (Right) Regulators of Cdk5 (in post-mitotic
neurons). Specific binding partners (e.g. p35, p25, p39, p29 or cyclin I) can activate Cdk5, whereas GSTP1, cyclin D1 or cyclin E inhibit it. Cdk5 is also
differentially regulated through phosphorylation of Y15, which increases its activity – although not by Myt1 and Wee1, but by Eph, Abl or Fyn. Green arrows
indicate positive regulation of Cdk activity, red dashed arrows indicate negative regulation through phosphorylation. Green ovals indicate activating proteins, red
ovals or boxes indicate inhibiting proteins.
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deregulation of Cdk5 through increased formation of p25 (Sato
et al., 2011).
Although a few in vitro studies have shown that the complex
between Cdk5 and p25 displays a higher activity than that between
Cdk5 and p35, other studies have reported comparable activities
(Peterson et al., 2010). The relative catalytic activities of the Cdk5–
p35 and Cdk5–p25 complexes in vivo are not known. Nevertheless,
because p25 is resistant to ubiquitin-mediated proteolysis and
has a fivefold longer half-life than p35 (Patrick et al., 1999), it
substantially extends the activation period of Cdk5, leading to
hyperphosphorylation of its normal physiological targets, which
is detrimental to the cells. For example, in developing axons,
tau is phosphorylated by Cdk5–p39, but not by Cdk5–p35,
resulting in neuritic growth in a region-specific manner that is
regulated during development (Takahashi et al., 2003). However,
under neurotoxic conditions, Cdk5–p25 hyperphosphorylates
tau, which aggregates to form neurofibrillary tangles in AD.
Likewise, under physiological conditions, Cdk5 phosphorylates
neurofilament heavy chain (NF-H) at its tail domain on Lys-Ser-
Pro motifs. This promotes the assembly of neurofilaments in the
axon, resulting in axonal support and neurite outgrowth while
reducing axonal transport (Shea et al., 2004). However, in several
neurological disorders, they are hyperphosphorylated and
aggregate in cell bodies. Several kinases including deregulated
GSK3B, PKA, MAPK, CaMK2 or Cdk5–p25 are known to
substantially contribute to aberrant phosphorylation of NFs in
diseased neurons (Shea et al., 2004). Thus, owing to the prolonged
half-life of p25 compared with p35, the Cdk5–p25 complex
hyperphosphorylates its physiological targets leading to neuronal
toxicity.
Recent studies have further highlighted that Cdk5–p35 and
Cdk5–p25 complexes display both overlapping and distinct
subcellular distribution. Whereas the Cdk5–p35 complex
mainly localizes to the perinuclear region and at the plasma
membrane with less distribution in the nucleus (Fu et al., 2006;
Asada et al., 2008), the Cdk5–p25 complex is largely cytosolic
and nuclear. Thus, the mislocalization of the Cdk5–p25 complex
to the cytoplasm and the nucleus is considered to be another
crucial factor that leads to Cdk5-induced neurotoxicity. For
example, the mislocalization allows the access of Cdk5–
p25 to a variety of new targets, e.g. GM130, peroxiredoxin 1,
peroxiredoxin 2, lamin A, lamin B1, Cdc25A, Cdc25B and
Cdc25C, which causes neurotoxicity (Chang et al., 2010; Chang
et al., 2011; Chang et al., 2012; Sun et al., 2008a; Sun et al.,
2008b; Sun et al., 2009). The Cdk5-p25 complex causes aberrant
Golgi fragmentation by phosphorylating GM130 and promotes
oxidative stress by phosphorylating peroxiredoxins (Sun et al.,
2008a; Sun et al., 2008b). Cdk5–p25 triggers dispersion of
the nuclear envelop by phosphorylating lamins, and promotes
aberrant activation of the cell cycle by phosphorylating Cdc25A,
Cdc25B and Cdc25C (Chang et al., 2011; Chang et al., 2012).
Thus, the Cdk5–p25 complex is believed to cause neurotoxicity,
both through hyperphosphorylation of its physiological targets
and phosphorylation of non-physiological targets.
Interestingly, p10, the other cleavage product of p35, was
assumed to have no function, as it is rapidly degraded by
ubiquitylation. However, a recent study showed that p10
possesses a unique pro-survival domain that is essential for the
physiological functions of Cdk5–p35 in neurons. Indeed, loss of
the p10 domain results in Cdk5–p25-mediated toxicity and
neurodegeneration in vivo (Zhang et al., 2012). These findings
suggest that p10 imparts a distinct substrate specificity to
the Cdk5–p35 complex compared with Cdk5–p25. More
interestingly, ectopic expression of p10 alone (without the p25
domain) can protect neurons from Cdk5–p25-induced toxicity;
however, p10 does so without any association with the Cdk5–p25
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Fig. 2. Regulation of the subcellular localization and stability
of p35 in response to Cdk5-mediated phosporylation. (Top) In
fetal and adult brains p35 is phosphorylated by Cdk5 at amino acid
residue S8, which promotes a cytoplasmic localization of the
Cdk5–p35 complex. (Middle) Fetal brain has high levels of p35
phosphorylated at T138 mediated through Cdk5. This has three
known consequences: (i) Inhibition of calpain-mediated cleavage
of p35 to p25. In fetal brain, neurotoxicity is, thereby, prevented
despite a high activity of Cdk5. (ii) Inhibition of the ability of p35 to
bind MTs. p35-induced MT bundling and neurite outgrowth in
neurons is, thereby, prevented. (iii) The level of degradation of p35
is increased, thereby reducing Cdk5 activity. (Bottom) In adult
brain, p35 phosphorylation at T138 is not detected anymore,
presumably because this residue becomes dephosphorylated by
PP1 or PP2A. p35 that is not phosphorylated at T138 (regardless
of S8 phosphorylation) is susceptible to calpain-mediated
cleavage, yielding p10 and p25, which then leads to the formation
of the neurotoxic complex Cdk5–p25. Furthermore, p35 not
phosphorylated at T138 binds to microtubules (MTs), leading to
their bundling and to neurite outgrowth. It also sequesters p35
away from Cdk5, thereby reducing its activity. Moreover, p35 not
phosphorylated at T138 has a half-life longer than its
phosphorylated counterpart at T138.
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complex. This finding suggests that other cellular factors work with
p10 in inhibiting Cdk5–p25-mediated neurotoxicity, but future
studies are needed to unravel this mechanism. Notably, the pro-
survival function of p10 augurs well for developing interventions
against deregulated Cdk5-mediated signaling pathways.
p39 and p29
p39 is an isoform of p35 and another neuron-specific activator of
Cdk5 (Fig. 1), but the pattern of p39 expression is distinct from that
of p35. Whereas p35 is highly expressed in the cerebral cortex of
developing brains, p39 is prominently expressed in embryonic and
adult hind brains, and the postnatal cerebral cortex (Zheng et al.,
1998; Jeong et al., 2003; Takahashi et al., 2003). Genetic studies
have shown that, although functions of p39 largely overlap with
those of p35, it also has several unique functions. Cdk52/2 mice
display perinatal lethality with extensive defects in several brain
regions (Ohshima et al., 1996), whereas p39 deficiency does not
result in any apparent abnormalities. However, p35 and p39
double-knockout mice display a phenotype that is identical to that
of Cdk52/2mice (Ko et al., 2001), highlighting p35 and p39 as the
main Cdk5 activators in the brain.
Similar to p35, p39 possesses a N-terminal myristoylation site,
although p39 has a longer half-life than p35 (Minegishi et al.,
2010). p39 is also cleaved by calpain to yield p10 and p29 under
neurotoxic conditions (Patzke and Tsai, 2002). p39 contains a
small insertion at the C-terminus (amino acids 329–366 – that is
absent in p35) – which binds the intracellular protein muskelin,
recruiting it to the cell periphery where it regulates cell adhesion
and cytoskeletal organization (Ledee et al., 2005). Muskelin
also facilitates transport of the GABA receptor along actin
and MT networks through different motor protein complexes
(Heisler et al., 2011), suggesting that p39-mediated recruitment of
muskelin at the cell periphery is essential for its physiological
function.
In vitro, the Cdk5–p39 complex displays a similar enzymatic
activity and substrate specificity to that of the Cdk5–p35;
however, compared with Cdk5–p35 signaling, little is known
about the activity of Cdk5–p39 in vivo, presumably because it has
been difficult to isolate an active Cdk5–p39 complex. The
catalytic activity of Cdk5–p39 is instantly abolished when it is
extracted from the cell membrane (Ko et al., 2001). It has also
proven challenging to reconstitute Cdk5–p39 in vitro, as the
detergent that can stabilize Cdk5–p35 destabilizes the Cdk5–
p39 complex (Yamada et al., 2007). Similar to p35, Cdk5
also regulates the cytoplasmic retention of p39 by direct
phosphorylation of p39 at S8 (Asada et al., 2012). Likewise,
Cdk5 also phosphorylates p39 at S173 (equivalent to T138 for
p35; Fig. 2); however, whether this phosphorylation regulates
p39 stability has not been analyzed. In addition, Cdk5
phosphorylates p39 at T84, a unique site not shared by p35.
Compared with p35, p39 has a higher tendency to accumulate in
the nucleus, which is inhibited by Cdk5 through phosphorylation
of T84 (regardless of whether S8 is phosphorylated or not)
(Asada et al., 2012). These results suggest that the subcellular
localization of the different Cdk5-activator complexes is
determined by the kinase activity of Cdk5.
Cyclin D
Initial studies showed that cyclin D1 and cyclin D3 associate with
Cdk5 in human diploid fibroblasts, but have no influence on its
activity (Xiong et al., 1992; Bates et al., 1994). However, Guidato
et al. reported that cyclin D2 modulates the activity of the
Cdk5–p35 complex, although the specific mechanism was not
investigated in this study (Guidato et al., 1998). In agreement, a
recent study revealed that cyclin D1 modulates Cdk5–p35
activity, possibly by competing with p35 binding to Cdk5
(Modi et al., 2012). Importantly, unlike cyclin D2, cyclin D1 is
expressed at high levels in adult mouse brain, particularly in
hippocampal pyramidal neurons (De Falco et al., 2004). Cyclin
D1 can be further upregulated upon exposure to Ab (Modi et al.,
2012), suggesting that similar to cyclin E, it might be a
physiologically or pathologically relevant inhibitor of Cdk5
(Fig. 1). A recent work uncovered a role for cyclin D2 as a
cardiogenic coactivator of GATA4 and suggests a paradigm for
cell-specific effects of cyclin D proteins (Yamak et al., 2014).
Cyclin E
Cyclin E is normally expressed in proliferating cells, where it binds
and activates Cdk2 (Koff et al., 1991). The Cdk2-cyclin E complex
is critical for G1/S transition of the cell cycle and DNA synthesis
(Tsai et al., 1993). Recent studies have shown that cyclin E is also
highly expressed in adult brain where it forms a complex with
Cdk5 (Odajima et al., 2011). Interestingly, instead of activating
Cdk5, the binding of cyclin E inactivates Cdk5 and sequesters it
away from its normal activators p35 and p39 (Odajima et al.,
2011). Moreover, cyclin-E-mediated sequestering of Cdk5
promotes dendritic growth, synaptic plasticity and memory
formation in transgenic animal models, suggesting that cyclin-E-
mediated inhibition of Cdk5 is physiologically relevant (Fig. 1).
Cyclin I
Cyclin I was initially isolated from human forebrain; however,
because cyclin I failed to associate with any of the classic Cdks,
its function was not investigated at the time (Nakamura et al.,
1995). Recently, reduced Cdk5 activity has been observed
in cyclin-I-deficient mice (Brinkkoetter et al., 2009). The
authors further noticed that the Cdk5–cyclin-I complex
predominantly exists in post-mitotic cells (e.g. neurons and
podocytes). However, a recent study reported that cyclin I is also
involved in cell cycle progression (Nagano et al., 2013).
In post-mitotic cells, the Cdk5–cyclin-I complex induces cell
survival through transcription of the anti-apoptotic proteins B-cell
lymphoma 2 (Bcl2) and B-cell lymphoma-extra large (Bcl-XL;
officially known as BCL2L1) (Brinkkoetter et al., 2009;
Brinkkoetter et al., 2010). In contrast, the Cdk5–p35 complex
does not induce the transcription of Bcl2 and Bcl-XL, suggesting
that cyclin I binding either recruits Cdk5 to different pool of
substrates or alters it substrate specificity. Future studies are needed
to evaluate this mechanism. Likewise, it will be interesting to see
whether an alteration in cyclin I levels contributes to the Cdk5
deregulation observed in neurodegenerative diseases. A potential
decrease in cyclin I levels might allow Cdk5 to bind other activators
(such as p35 or p25), thereby resulting in a certain phenotype and
vice versa.
GSTP1
The aberrant formation of p25 in neurodegenerative neurons is
regarded as the primary mechanism that leads to the deregulation
of Cdk5 in neurological disorders (Patrick et al., 1999; Tseng
et al., 2002; Cruz et al., 2003). However, several research groups
have reported unaltered or slightly reduced levels of p25 in AD
patients when compared with age-matched unaffected individuals
(Taniguchi et al., 2001; Yoo and Lubec, 2001; Tandon et al.,
2003), suggesting that other regulatory factors for Cdk5 exist or
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that there are alternative molecular mechanisms for the
deregulation of Cdk5.
Recently, we have shown that glutathione-S-transferase P
(GSTP1) is a regulator of Cdk5 in neuronal cell lines, cancer cell
lines and AD brains (Sun et al., 2011; Fig. 1). GSTP1 is a
detoxifying enzyme that eliminates free radicals by using the
reduced glutathione motif. GSTP1 is widely expressed, with
especially high levels in the brain (Berhane et al., 1994). GSTP1
activity and levels are reduced in AD neurons, suggesting that
GSTP1 downregulation acts as a trigger that promotes oxidative
stress and causes neurodegeneration in AD (Lovell et al., 1998).
Our study revealed that GSTP1 inhibits the activity of Cdk5
through two mechanisms. First, it competes with p35 and p25 for
Cdk5 binding. Second, GSTP1 scavenges molecules associated
with oxidative stress, a potent activator of Cdk5 activity. Most
importantly, we observed an inverse correlation between GSTP1
levels and the activity of Cdk5 in various cancers, as well as in
neuronal cell lines and AD brains, suggesting that GSTP1 is a
common regulator of Cdk5 that inhibits its activity in different
tissues (Sun et al., 2011).
Transcriptional regulation
Transcriptional regulation of p35
Transcription of p35 is promoted by several stimuli, including
nerve growth factor (NGF) (Harada et al., 2001), brain-derived
neurotrophic factor (BDNF) (Lim et al., 2008), retinoic acid (Lee
and Kim, 2004), interferon c (IFNG) (Song et al., 2005), 1,25-
dihydroxyvitamin D3 (Chen et al., 2004), tumor necrosis factor
alpha (TNFa) (Utreras et al., 2009) and laminin (Paglini et al.,
1998). These factors activate extracellular regulated MAP
kinases 1 and 2 (MAPK1 and MAPK3, hereafter referred to as
Erk1/2) signaling, which upregulate p35 gene expression through
the participation of the transcription factor early growth response
protein 1 (EGR1) (Fig. 3). Fas engagement also activates Erk1/2
signaling leading to p35 transcription in dorsal root ganglia;
however, whether this is due to EGR1 upregulation is not known
(Desbarats et al., 2003).
Apart from stimulating the Erk1/2–EGR1 pathway, which
increases p35 transcription, TNFa also activates the p38 MAPK
(MAPK14), Jun N-terminal kinase (JNK) and NF-kB pathways,
all of which inhibit the transcription of p35 (Utreras et al., 2009)
(Fig. 3). In contrast, BDNF stimulates the Erk1/2–EGR1 pathway
to increase p35 transcription, as well as the phosphoinositide-3
kinase (PI3K) pathway to increase p35 protein levels in striatal
neurons (Bogush et al., 2007) (Fig. 3). It is not known whether
P13K-mediated increase in p35 levels is at transcriptional or post-
translational level (Bogush et al., 2007) (Fig. 3).
The transcription factors Brn-1 and Brn-2 (POU3F3 and
POU3F2, respectively) also participate in the gene expression of
p35 and p39. Similar to Cdk5-knockout mice, Brn-1 and Brn-2
deficient mice exhibit severe cortical lamination defects (McEvilly
et al., 2002). These mice lack p35 and p39 mRNAs in migrating
neurons of the cortex and hippocampus, thereby strongly indicating
that these transcription factors regulate the transcription of p35 and
p39 (Fig. 3). In addition, heat shock factor Hsf2 binds to the p35
promoter increasing p35 expression (Chang et al., 2006).
Accordingly, the cerebral cortex of Hsf22/2 mice displays a
mispositioning of neurons within superficial layers, a phenotype
that is consistent with p35 deficiency (Chang et al., 2006).
Transcriptional regulation of Cdk5
Expression ofCdk5 is also upregulated through the Erk1/2 pathway
but is mediated by the transcription factors Fos and cAMP-
responsive element binding protein (CREB) (Lee and Kim, 2004)
(Fig. 4). Accordingly, inhibition of Erk1/2 prevents retinoic-acid-
induced expression of Cdk5, whereas constitutively active MEK1
induces Cdk5 expression in neuroblastoma cells (Lee and Kim,
2004). Interestingly, Cdk5 also inhibits the gene expression of p35
though a feedback mechanism that downregulates activation of
Erk1. Here, Cdk5 directly phosphorylates MEK1 (MAP2K1) – the
Fig. 3. Transcriptional regulation of p35. Several stimuli,
including BDNF, NGF, interferon-c (IFN-c), laminin, retinoic acid
(RA), 1,25-dihydroxyvitamin D3 (D3) and TNFa, activate Erk1/2,
which upregulate the transcription of p35 through the transcription
factor EGR1. FasL engagement also increases the transcription of
p35 through the Erk1/2 pathway, but it is unknown whether this
occurs through upregulation of EGR1. In addition to the Erk1/2
pathway, BDNF also activates the PI3K pathway leading to
increased levels of p35 protein, although it is unclear whether this
is mediated at mRNA or protein level. TNFa increases transcription
of p35 through the Erk1/2 pathway, but inhibits it through the
activation of the p38, JNK and NFkB pathways. miR-103 and miR-
107 inhibit the expression of p35 post-transcriptionally. RAR,
retinoic acid receptor; VDR, vitamin D3 receptor; RXR, retinoid
X receptor.
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upstream activator of Erk1 – and represses its activity, leading to
repression of p35 transcription (Sharma et al., 2002).
Transcription of Cdk5 is also stimulated by dFosB, a FosB
gene product and a member of the Jun family of transcriptional
factors. dFosB-overexpressing transgenic mice have increased
levels of Cdk5 mRNA and protein (Chen et al., 2000; Bibb et al.,
2001). Dopamine, cocaine and electroconvulsive seizures, all of
which increase dFosB levels promote the transcription of Cdk5
(Fig. 4).
Post-transcriptional regulation of p35 and Cdk5
MicroRNAs (miRNAs) are emerging as an important regulator
for various pathways and have been shown to be involved in
several CNS diseases, including neurodegenerative disorders
(Long and Lahiri, 2012). For example, several miRNA species,
such as miR-101, miR-153 and miR-339-5p are dysregulated in
AD (Long and Lahiri, 2011a; Long and Lahiri, 2011b; Long
et al., 2012; Long et al., 2014). In this context, p35 expression
can be post-transcriptionally suppressed by miRNAs 103 and
107 (miR-103 and miR-107, respectively) (Moncini et al.,
2011). miR-103 and miR-107 directly bind to 39UTR of p35
and repress its translation (Fig. 3). Other miRNAs, such as
miR-26b, participate in nuclear export and activation of Cdk5
(Absalon et al., 2013). Thus, the regulation of Cdk5 activity by
specific miRNAs might be important both under physiological
and pathological conditions.
Post-translational regulation of Cdk5
Although binding to a protein partner is obligatory for Cdk5
activation, its activity can be further tweaked by phosphorylation
or S-nitrosylation.
Phosphorylation
Cdk5 possesses three conserved phosphorylation sites that are
common among the Cdk family: Thr14, Tyr15 and Ser159. But
the mode of Cdk5 activation differs from that of its family
members. The kinases Wee1 and Myt inhibit the activity of other
Cdks by dual phosphorylation at, for example, Thr14 and Tyr15
in the case of Cdk1; however, these kinases are unable to
phosphorylate Cdk5 at either position (Fattaey and Booher, 1997)
(Fig. 1). Instead, the kinases Abl, ephrin receptor A (EphA)
and Fyn phosphorylate Cdk5 at Tyr15, leading to its activation
(Fig. 1), thereby promoting neuronal migration, neurite outgrowth
and synaptogenesis (Zukerberg et al., 2000; Sasaki et al., 2002;
Cheng et al., 2003). Abl-mediated phosphorylation of Tyr15 can
also hyperactivate Cdk5, resulting in neurodegeneration (Lin et al.,
2007; Cancino et al., 2011).
Another difference between Cdk5 and other Cdks is the effect
of Cdk7 on the latter. Cdk7 is known to phosphorylate Cdks in the
T loop, e.g. Thr160 in Cdk2 and Thr161 in Cdk1, which strongly
activates them (e.g. a 200-fold activation of Cdk2) (Fig. 1).
However, Cdk7 is unable to phosphorylate the corresponding
Ser159 residue in Cdk5 (Poon et al., 1997). It remains unclear
whether Cdk5 is phosphorylated at Ser159 in cells; however, the
corresponding phospho-mimetic Cdk5 mutant (S159E) is
defective in binding p35, suggesting that Cdk5 phosphorylation
at this site inhibits its activity (Tarricone et al., 2001).
S-Nitrosylation
Cdk5 is S-nitrosylated at Cys83 and Cys157 when treated with S-
nitrosocysteine or S-nitrosoglutathione in vitro (Qu et al., 2011).
Interestingly, nitrosylating agents at low concentration (200 mM)
augment the activity of Cdk5 (Qu et al., 2011), whereas they
inhibit it at high concentration (1 mM) (Zhang et al., 2010). In
neurons, Cdk5 is S-nitrosylated by neuronal nitric oxide synthase
(NOS1), which in turn transnitrosylates the mitochondrial fission
protein Drp1, leading to mitochondrial fission in dendritic spines
(Qu et al., 2011). Thus, S-nitrosylated Cdk5 not only has higher
kinase activity but also acts as a nascent transnitrosylase.
Importantly, S-nitrosylation of Cdk5 is enhanced in the
presence of Ab and N-methyl-D-aspartate (NMDA) (Qu et al.,
2011; Qu et al., 2012), suggesting that deregulated Cdk5 also
induces neurotoxicity through aberrant S-nitrosylation reactions
under pathological conditions.
Cdk5 in the brain
Cdk5 and synaptic plasticity
Notably, transgenic animal models have revealed contrasting roles
of Cdk5 in learning and the formation of memory. A positive role
of Cdk5 in promoting synaptic plasticity was identified in p352/2
mice, which display depotentiation – the erasure of long-term
potentiation (LTP) – and the defective induction of long-term
depression (LTD) (Ohshima et al., 2005). Likewise, Cdk5 is
transiently upregulated in mice that are exposed to stress and
facilitates context-dependent fear conditioning (Fischer et al.,
2002). Similarly, Cdk5f/f/T29 mice – in which Cdk5 is selectively
ablated in the CA1 pyramidal neurons of the hippocampus
– revealed impaired memory function and synaptic plasticity
(Guan et al., 2011).
In contrast, Hawasli et al. demonstrated that the initial loss of
Cdk5 in Cdk5 conditional knockout mice results in enhanced
LTP, NMDA-receptor-mediated synaptic plasticity and improved
performance in hippocampal behavioral learning tasks, which
highlights a negative role of Cdk5 in learning and memory
Fig. 4. Transcriptional regulation of Cdk5. During neuronal differentiation,
retinoic acid (RA) increases transcription of Cdk5 through at least two
mechanisms: (1) RA-mediated increase of ERK1/2 activity leads to
upregulation of the transcriptional factors Fos and Jun; they then bind to the
AP-1-binding site within the Cdk5 promoter, thus inducing transcription of
Cdk5. (2) Treatment with RA increases PKA activity, resulting in
phosphorylation of CREB, which, in turn, results in its binding to the cAMP
response element (CRE) at the Cdk5 promoter inducing Cdk5 expression.
Moreover, Cdk5 expression is also enhanced in response to chronic cocaine
use and electroconvulsive seizures (ECS) through the transcription
factor dFosB.
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formation (Hawasli et al., 2007). Likewise, tau-tubulin
kinase-1 (TTBK1)-overexpressing transgenic mice, which
display elevated Cdk5 activity, expedite calpain-mediated
degradation of the NMDA receptor subtype 2B (NR2B),
causing learning deficits (Sato et al., 2008). Taken together,
these findings imply that Cdk5 not only promotes LTP and LTD,
but also counteracts changes induced by LTP and LTD to
maintain neuronal network stability, thereby functioning as a
homeostatic regulator of synaptic plasticity.
Cdk5 and pain
Cdk5 facilitates heat hyperalgesia-associated inflammatory pain in
the dorsal root ganglion (DRG) of mice and rats (Pareek et al.,
2006; Pareek et al., 2007; Yang et al., 2007). Cdk5 and p35 are
abundantly expressed in the DRG, trigeminal ganglion and spinal
cord. Their expression further increases during peripheral
inflammatory response, followed by subsequent cleavage of p35
to p25, leading to hyperactivation of Cdk5 (Pareek et al., 2006). In
agreement with this molecular pathway, p35-knockout mice display
pain hyposensitivity to the thermal stimuli when compared with
wild-type mice, whereas overexpression of p35 has the opposite
effect (Pareek et al., 2006). Similarly, Cdk5 conditional knockout
mice display palpable hypoalgesia (Pareek et al., 2007).
Cdk5 and drug addiction
Cocaine enhances synaptic dopamine levels in the striatum by
inhibiting dopamine re-uptake at axon terminals. An acute dose
of cocaine increases dopamine levels, which activates PKA.
PKA phosphorylates protein phosphatase 1 regulatory subunit 1B
(DARPP-32) at residue T34, which potentiates dopamine
signaling (Nishi et al., 2000). In contrast, chronic exposure of
cocaine upregulates mRNA levels of Cdk5 and p35 in reward-
associated brain regions by persistent upregulation of the
transcription factor dFosB (Bibb et al., 2001; Kelz and Nestler,
2000; Fig. 4). Increase in Cdk5 activity and protein levels
results in elevated levels of DARPP-32 phosphorylated at T75
and inhibition of PKA activity, resulting in depotentiation of
dopamine signaling (Bibb. et al., 2001). Cdk5, thus, elicits an
adaptive homeostatic response that irreversibly dedicates the
affected neurons to a process of cytoarchitectural changes,
leading to addiction.
Cdk5 in neurological diseases
Significantly higher activity of Cdk5 has been observed in brains of
AD patients compared with non-demented individuals (Lee et al.,
1999). In a mouse model, intracerebroventricular injection of the
Ab(1–40) peptide hyperactivates Cdk5 because of the formation of
p25, and causes tau hyperphosphorylation, aberrant cell cycle
induction, synaptotoxicity and neuronal loss (Lopes et al., 2010).
Transgenic mice that express tetracycline-inducible p25 show
substantial brain atrophy, synaptic dysfunction and NFT formation
(Cruz et al., 2003). Wen et al. further showed that overexpression of
p25 increases Cdk5-mediated transcription of BACE1, leading to
aberrant Ab processing (Wen et al., 2008). Therefore, Cdk5
inhibitors might prevent Ab and neurofibrillary pathology and
synaptic loss in AD patients (Monaco, 2004; Glicksman et al., 2007).
In mouse models of PD, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-treatment results in higher levels of
the Cdk5–p25 complex in dopaminergic neurons, leading to
neuronal death (Smith et al., 2003). MPTP treatment destroys
dopaminergic neurons in the substantia nigra of the brain, causing
irreversible symptoms of PD. Cdk5 also induces autophagy in the
PD model through the phosphorylation of endophilin B1 (Wong
et al., 2011). Deregulation of autophagy has been linked to PD
pathogenesis, and autophagosome accumulation occurs in the
brains of both PD patients and PD mouse models (Anglade et al.,
1997; Zhu et al., 2003).
In stroke-affected patients, levels of phosphorylated Cdk5, p35
and p25 are substantially increased in the affected but not
in healthy neurons, suggesting a link between Cdk5 and the
pathogenesis of ischemia (Mitsios et al., 2007). Cdk5 inhibition
confers neuroprotection in in vivo models of ischemia and stroke,
underscoring its crucial role in disease progression (Menn et al.,
2010). In the case of HD, Cdk5 deregulation is linked to striatal
neuronal death (Paoletti et al., 2008).
Cdk5 as a drug target
Based on these different roles of Cdk5 in the brain, Cdk5 is
considered an attractive drug target in order to treat multiple
neurological disorders that involve learning and memory deficits,
and defective motor functions. Although there are several
known high-potency Cdk5 inhibitors, they concurrently show
poor selectivity and specificity because they inhibit other Cdks
with equal or higher potency. As a result, despite their potential,
Cdk5 inhibitors have – owing to serious side effect – thus far not
been successful in clinical trials. Given the pivotal role of Cdk5 in
the brain, it would be beneficial to develop Cdk5-specific
inhibitors, or engineer inhibitors that selectively abrogate the
interaction of Cdk5 with p25 but not with p35. In this respect, the
finding regarding the pro-survival function of p10 (the cleaved
product of p35) is encouraging and can potentially be used to
selectively abrogate Cdk5–p25-mediated neurotoxicity (Zhang
et al., 2012). Likewise, Cdk5 inhibitory peptide (CIP), a 125
amino acid fragment of p25 (Zheng et al., 2002), effectively and
specifically inhibits the hyperactivation of Cdk5–p25 in vivo
(Sundaram et al., 2013). In CIP-p25-transgenic mice, expression
of CIP rescues the neurodegenerative pathologies caused by
deregulation of Cdk5–p25 without compromising the normal
neurodevelopment. Such an approach would allow to retain the
physiological functions of Cdk5 while putting a brake on its
neurotoxic behavior.
Conclusions
Research over the past 25 years has not only uncovered numerous
physiological and pathological roles of Cdk5, but also revealed an
increasing number of Cdk5 regulators. Whereas earlier studies
mainly focused on p35 and p39 as the predominant regulators of
Cdk5 in the CNS, emerging studies have identified multiple
mechanisms that regulate Cdk5 at transcriptional, post-
transcriptional and post-translational levels. Recent studies have
also identified several so far unknown protein regulators of Cdk5,
including cyclin D1, cyclin E, cyclin I and GSTP1. Whereas
cyclin D1, cyclin E and GSTP1 inhibit Cdk5 activity, cyclin I is
an activator of Cdk5. A retrospective analysis of these modulators
in normal and diseased tissue specimens might uncover alternate
modes of Cdk5 deregulation in various neurological disorders. It
is also likely that many more of Cdk5 regulators exist, which
might affect Cdk5 localization, substrate specificity, activity and
levels. Targeting these regulators might provide an alternative
strategy for the development of effective therapeutic
interventions that arise from deregulation of Cdk5 in conditions
such as AD, HD, PD, ischemia and stroke, frontotemporal
dementia, amyotrophic lateral sclerosis and Niemann-Pick
disease type C.
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